ATE211129T1 - Inhibitoren von beta-amyloid-protein-herstellung - Google Patents

Inhibitoren von beta-amyloid-protein-herstellung

Info

Publication number
ATE211129T1
ATE211129T1 AT94928637T AT94928637T ATE211129T1 AT E211129 T1 ATE211129 T1 AT E211129T1 AT 94928637 T AT94928637 T AT 94928637T AT 94928637 T AT94928637 T AT 94928637T AT E211129 T1 ATE211129 T1 AT E211129T1
Authority
AT
Austria
Prior art keywords
amyloid protein
inhibitors
beta
protein production
alzheimer
Prior art date
Application number
AT94928637T
Other languages
English (en)
Inventor
Barbara Cordell
Daniel Schirlin
Norton P Peet
Jeffrey N Higaki
Dorsselaer Viviane Van
Michael R Angelastro
Original Assignee
Merrell Pharma Inc
Scois Nova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc, Scois Nova Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of ATE211129T1 publication Critical patent/ATE211129T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94928637T 1993-10-01 1994-09-20 Inhibitoren von beta-amyloid-protein-herstellung ATE211129T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93402398 1993-10-01
PCT/US1994/010679 WO1995009838A1 (en) 1993-10-01 1994-09-20 INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION

Publications (1)

Publication Number Publication Date
ATE211129T1 true ATE211129T1 (de) 2002-01-15

Family

ID=8214751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94928637T ATE211129T1 (de) 1993-10-01 1994-09-20 Inhibitoren von beta-amyloid-protein-herstellung

Country Status (19)

Country Link
EP (1) EP0721449B1 (de)
JP (1) JPH09505281A (de)
KR (1) KR100316865B1 (de)
CN (1) CN1078886C (de)
AT (1) ATE211129T1 (de)
AU (1) AU687449B2 (de)
CA (1) CA2171882C (de)
DE (1) DE69429527T2 (de)
DK (1) DK0721449T3 (de)
ES (1) ES2170104T3 (de)
FI (1) FI961438A0 (de)
HU (1) HU221629B1 (de)
IL (1) IL111078A (de)
NO (1) NO308029B1 (de)
NZ (1) NZ274074A (de)
PT (1) PT721449E (de)
TW (1) TW264480B (de)
WO (1) WO1995009838A1 (de)
ZA (1) ZA947529B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ284766A (en) * 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
ES2161293T3 (es) * 1994-06-02 2001-12-01 Merrell Pharma Inc Derivados de enol acilados como profarmacos de inhibidores de la elastasa.
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
US6172044B1 (en) 1995-12-01 2001-01-09 Aventis Pharmaceuticals Inc. Acylated enol derivative of α-ketoesters and α-ketoamides
CA2191924A1 (en) 1995-12-05 1997-06-06 Kevin Felsenstein 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of .beta.-amyloid protein production
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US6207710B1 (en) 1996-11-22 2001-03-27 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
ID22275A (id) * 1996-11-22 1999-09-23 Elan Pharm Inc Komposisi farmasi yang terdiri dari derivat asam amino n-(aril atau heteroaril) dan metode untuk menghambat pelepasan b-amiloid peptida dan atau sintesisnya dengan menggunakan senyawa tersebut
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6642261B2 (en) 1997-11-21 2003-11-04 Athena Neurosciences, Inc. N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6117901A (en) 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
US6096782A (en) * 1996-11-22 2000-08-01 Athena Neurosciences, Inc. N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
AR016751A1 (es) * 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
US6153652A (en) 1996-11-22 2000-11-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6506782B1 (en) 1998-02-27 2003-01-14 Athena Neurosciences, Inc. Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
EP1159273A1 (de) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Verbindungen, verwendbar als reversible inhibitoren von cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
WO2001092235A1 (en) 2000-06-01 2001-12-06 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
CN1494425B (zh) 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
ES2373875T3 (es) 2002-03-05 2012-02-09 Transtech Pharma, Inc. Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage.
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR100851035B1 (ko) 2005-08-23 2008-08-11 대한민국 GCP-Ⅱ를 유효성분으로 함유하는 β-아밀로이드의 뇌내축적 예방 및 치료용 약학적 조성물과 치료제 스크리닝용조성물 및 이를 이용한 스크리닝 방법
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
JP5783659B2 (ja) 2009-12-22 2015-09-24 セファロン、インク. プロテアソーム阻害剤およびその調製、精製および使用のための方法
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
RU2721845C2 (ru) 2015-12-30 2020-05-25 Нойборон Медтех Лтд. СОЕДИНЕНИЕ ДЛЯ СПЕЦИФИЧЕСКОГО СВЯЗЫВАНИЯ С β-АМИЛОИДОМ
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
EA201990069A1 (ru) 2016-06-21 2019-06-28 ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи Производные гетероциклического пролинамида
WO2019152724A1 (en) * 2018-02-02 2019-08-08 Prozyme, Inc. Methods and kits for using blocked 2-aa for glycan analysis
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (de) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metaboliten von [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
CA1341029C (en) * 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
ZA905737B (en) * 1989-07-26 1991-05-29 Merrell Dow Pharma Novel peptidase inhibitors
EP0572547A1 (de) * 1991-02-22 1993-12-08 The Du Pont Merck Pharmaceutical Company Substituierte alpha-amino aldehyde und derivate
CA2071621C (en) * 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives

Also Published As

Publication number Publication date
FI961438A (fi) 1996-03-29
NO308029B1 (no) 2000-07-10
NZ274074A (en) 1997-11-24
FI961438A0 (fi) 1996-03-29
PT721449E (pt) 2002-06-28
HU221629B1 (hu) 2002-12-28
AU687449B2 (en) 1998-02-26
NO961326D0 (no) 1996-04-01
KR960704839A (ko) 1996-10-09
DE69429527D1 (de) 2002-01-31
CN1132504A (zh) 1996-10-02
HUT74004A (en) 1996-10-28
DE69429527T2 (de) 2002-07-18
IL111078A (en) 1999-03-12
TW264480B (de) 1995-12-01
DK0721449T3 (da) 2002-04-22
KR100316865B1 (ko) 2002-11-29
EP0721449A1 (de) 1996-07-17
ES2170104T3 (es) 2002-08-01
HU9600832D0 (en) 1996-05-28
AU7799894A (en) 1995-05-01
CA2171882A1 (en) 1995-04-13
EP0721449B1 (de) 2001-12-19
IL111078A0 (en) 1994-11-28
ZA947529B (en) 1995-05-29
WO1995009838A1 (en) 1995-04-13
NO961326L (no) 1996-04-01
CN1078886C (zh) 2002-02-06
CA2171882C (en) 2001-12-04
JPH09505281A (ja) 1997-05-27

Similar Documents

Publication Publication Date Title
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
ATE153534T1 (de) Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DK0662948T3 (da) 2-amino-4-phenyl-4-oxosmørsyrederivater med kynureninase- og/eller kynurenin-3-hydroxylaseinhiberende virkning
BR0214295A (pt) Composto, método para tratar um paciente que tem ou prevenir um paciente de adquirir uma doença ou condição, e, método para produzir um composto
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
EA200501479A1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69805305T2 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69626916D1 (de) Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.
UA29106A (uk) Спосіб лікування вібраційної хвороби

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0721449

Country of ref document: EP

REN Ceased due to non-payment of the annual fee